A FOXP3+ cell-rich microenvironment associates with better overall survival after CAR-T cell therapy in relapsed/refractory B-cell lymphoma.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
3 patients but lacked statistical significance (1-year PFS 65% versus 54%, P = 0.
I · Intervention 중재 / 시술
CAR-T cell therapy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Notably, relapsed patients with high FOXP3 maintained high expression and responded better to subsequent treatments (P = 0.03). Our findings highlight the impact of tumor-infiltrating Tregs on CAR-T cell efficacy in lymphomas.
CAR-T cell therapy has revolutionized the treatment of non-Hodgkin B-lymphomas, but relapse rates remain unacceptably high, and resistance mechanisms are still unclear.
- p-value P = 0.006
- p-value P = 0.03
APA
Zanella S, Zucchinetti C, et al. (2026). A FOXP3+ cell-rich microenvironment associates with better overall survival after CAR-T cell therapy in relapsed/refractory B-cell lymphoma.. Cytotherapy, 28(3), 101997. https://doi.org/10.1016/j.jcyt.2025.10.007
MLA
Zanella S, et al.. "A FOXP3+ cell-rich microenvironment associates with better overall survival after CAR-T cell therapy in relapsed/refractory B-cell lymphoma.." Cytotherapy, vol. 28, no. 3, 2026, pp. 101997.
PMID
41240052 ↗
Abstract 한글 요약
CAR-T cell therapy has revolutionized the treatment of non-Hodgkin B-lymphomas, but relapse rates remain unacceptably high, and resistance mechanisms are still unclear. A key challenge of T-cell-based therapy is the immune-suppressive tumor microenvironment, which is rich in immune-suppressive cells, including regulatory T cells (Tregs). Tregs express FOXP3, CD3 and CD25, and their role in B-cell lymphomas treated with CAR-T cells remains uncertain. Using immunohistochemistry, we analyzed 31 pre-infusion and seven post-infusion paired biopsies from patients with relapsed/refractory B-cell lymphoma who received CAR-T cell therapy. Pre- infusion FOXP3+ cell percentages were assessed and correlated with response rate, progression-free survival (PFS), and overall survival (OS). Post-infusion biopsies were examined for FOXP3 changes. We identified 3% as the optimal FOXP3+ cut-off, defining low (≤3%) and high (>3%) FOXP3 groups. Patients with high FOXP3 had a better OS (1-year OS 94% versus 61%, P = 0.006). PFS also favored high FOXP3 patients but lacked statistical significance (1-year PFS 65% versus 54%, P = 0.41). Notably, relapsed patients with high FOXP3 maintained high expression and responded better to subsequent treatments (P = 0.03). Our findings highlight the impact of tumor-infiltrating Tregs on CAR-T cell efficacy in lymphomas.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.